Tumor vascular changes mediated by inhibition of oncogenic signaling. - Wikidata - thesis-toulmin - TriplyDB

Tumor vascular changes mediated by inhibition of oncogenic signaling.

Tumor vascular changes mediated by inhibition of oncogenic signaling.

http://www.wikidata.org/entity/Q33671385

about

Real-time visualization and quantitation of vascular permeability in vivo: implications for drug delivery Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy Efficacy via Reduction in Oxygen Demand Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells PI3K at the crossroads of tumor angiogenesis signaling pathways Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy Micro-ultrasound for preclinical imaging.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Stable tumor vessel normalization with pO₂ increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment.Three-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomography MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma AKT regulates NPM dependent ARF localization and p53mut stability in tumors.K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies.Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.Hypoxia-inducible factor in thyroid carcinoma Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck.A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation.Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.Longitudinal study of tumor-associated macrophages during tumor expansion using MRI.Combining two strategies to improve perfusion and drug delivery in solid tumors.Modulating the tumor microenvironment to increase radiation responsiveness.Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts.The tumor microenvironment in non-small-cell lung cancer Vascular strategies for enhancing tumour response to radiation therapy.The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?The Biological Role of PI3K Pathway in Lung Cancer.Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self-Renewal and Vascular Mimicry of Stem-Like Cells.Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia.Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis.

P2860

Q27306235-55A259A8-E7C6-4661-8A8F-AFCB00EAB11F Q28085180-A1D80308-A73A-48C1-8B1E-43D050F5BB70 Q28393898-7BAFE86C-069D-4081-9C71-1C0039CE4333 Q28396795-477AF40D-73B2-4FB7-918E-DB373140C5D9 Q29248893-9C5C7F55-DB50-4A67-BF01-5EC75FB9FEB5 Q30425612-EF28709F-7328-4F11-83BE-85EE4956BF36 Q30469815-8918A67A-482A-4972-A116-FB1B464EDB1A Q30471456-BB035E4B-DA2D-482D-9712-44EE6B1D744F Q30540976-7CF87CA6-7EE1-4D97-975E-C3DDD59D0F45 Q30640206-F2EDDB2C-6342-43A4-8CEF-D416EB242988 Q30881669-96A90C41-D653-47DC-B522-3EDA62B23866 Q33733303-9595F4E2-2842-41AF-8942-B3DE6DB98AA6 Q34168711-1FD55DC4-0455-4DF9-875A-31D702BD493A Q34227622-5622938B-FC45-42C6-9435-39AB3B83519A Q34406302-B3428E89-E2FC-4B5A-B1EA-6FBEF35123EB Q34742649-F1E3BD12-D3A4-4CB9-AB6F-4C988CE6D6DA Q34848038-1CF260BB-7D68-4823-B5A5-9E9A16C728D2 Q35099457-98D38BF7-C4F4-4324-861C-0E0B2CC89A52 Q35165488-CB9E52D7-76EE-4714-A92D-EA884741348E Q35184804-36E3F5E0-EB97-44E4-BD5C-D35C59F8AA89 Q35848165-396E19CA-EA89-4309-A558-CB02C902A25B Q35920966-619B4DCB-C88A-43C9-832D-9880D83D7790 Q35930433-55942857-19D3-4D2C-91BE-34079FFEFF2D Q35990334-D52A2BBC-C864-4B10-A23B-31736E80B77C Q36807950-89A7AE7C-8503-4489-A679-171B36ED7B62 Q37030917-9C26728D-46FC-4E8A-897F-DFFE1B80A8E3 Q37070294-41C63BA7-223D-4CBB-A73B-EF22E6C480AB Q37319733-1D138BBB-8C12-45CB-B9CE-5BF5D4212452 Q37613364-794E9CF2-1D83-4507-892D-FDAFE314C2DA Q37698857-AC6E206C-B3E0-4B2F-9F61-955B600BF5B2 Q37703365-70925D7E-7567-42E2-B3A5-B58C93C904E7 Q37777872-C4740754-82FE-4580-A462-54DCB8EBFBC5 Q38008461-25AA2D73-375E-4EF3-80E7-5E533D923019 Q38028791-6BBC6632-14F7-4638-B642-193D4BC59639 Q38107793-C268D4A4-540B-4313-BC4B-F4F1A061C26B Q38166599-BF7A367C-D1D8-464B-A99A-510AF5281B2B Q38869420-A2FB9380-768E-4C07-A145-5E0752DD101F Q38901912-A73EBD17-1071-4F72-8EBB-0A0DB82AF4FD Q39015424-5E7F05C9-D557-434E-976E-F48FAC21AE2D Q39094806-36ECB734-C1C4-4E09-BD5B-90A7580FB3D9

P2860

Tumor vascular changes mediated by inhibition of oncogenic signaling.

http://www.wikidata.org/entity/Q33671385

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Tumor vascular changes mediated by inhibition of oncogenic signaling.

@ast

Tumor vascular changes mediated by inhibition of oncogenic signaling.

@en

type

label

Tumor vascular changes mediated by inhibition of oncogenic signaling.

@ast

Tumor vascular changes mediated by inhibition of oncogenic signaling.

@en

prefLabel

Tumor vascular changes mediated by inhibition of oncogenic signaling.

@ast

Tumor vascular changes mediated by inhibition of oncogenic signaling.

@en

P1433

Q33671385-1B4B6D18-049A-4DB3-81FB-8ED13A1DBF8D

P1476

Q33671385-0671DBBB-8E87-4181-BADB-FEB15DA2DF0F

P2093

Q33671385-15A82BA3-8632-484D-863A-6EFF6F1C9976

Q33671385-23080D58-F962-4F69-B3EB-621CCA986FE5

Q33671385-4B7FC160-7C4D-43F2-8EE6-2A913A63E1AF

Q33671385-5BAD1E74-05FF-4361-BA45-222F66295AB1

Q33671385-A0CF200F-CF38-4902-B323-5C1A0A4A466D

Q33671385-AB6187E4-3912-4CA6-8EB1-CFC76680DFB9

Q33671385-EABD4C17-0CCC-4B97-B8E0-871775EE3418

Q33671385-F7F83A7C-383E-4CDC-ADDE-D7A41E896D7D

P2860

Q33671385-00EDBBB2-D690-4773-AA8D-6ECF4533072E

Q33671385-02046267-AED6-42E9-8D48-EF872CF68DFE

Q33671385-06201FEF-9A50-4FF9-B67E-E39D82ED77E9

Q33671385-0C3B7ECA-0905-4211-9682-92DAFF4EA486

Q33671385-0D4FAD50-AFDE-43BA-BCF8-42CFAE55DB82

Q33671385-141C5297-A7BA-4E29-808B-2F9ECFE9AEE0

Q33671385-21CFC383-10BA-4DB5-806B-41352EC5A09F

Q33671385-22459B4E-7035-4FD9-8D47-358F88A63724

Q33671385-26BD426A-A5F2-4BA1-BAED-CA6BC2F0037B

Q33671385-2A755000-77CA-4972-AA63-FBAA5DD4AFC3

P304

Q33671385-6D5B73DE-9207-423A-91EA-948F4A44FE64

P31

Q33671385-987A3D46-B499-4F16-AFC7-841B7315862C

P356

Q33671385-D45C2CDB-1221-4884-B8C9-53665157F6A2

P407

Q33671385-9C2A5B1F-2EED-465F-A434-ADE470CC406E

P433

Q33671385-65CE10A7-5B46-43B5-9A53-2520DF84B39C

P478

Q33671385-2FD7ECB1-91B9-489F-82D5-A16D3B1A6E1F

P577

Q33671385-A0B3D1F1-7524-4576-88F8-6799F78A4422

P698

Q33671385-C3937F74-F5E4-491F-A788-72E091910C7F

P932

Q33671385-147FD722-FE04-4BEA-9080-6C317BEAFE79

P356

0008-5472.CAN-09-0657

P1433

Cancer Research

P1476

Tumor vascular changes mediated by inhibition of oncogenic signaling.

@en

P2093

Cameron J Koch

http://www.w3.org/2001/XMLSchema#string

Eric J Bernhard

http://www.w3.org/2001/XMLSchema#string

Jae Hong Im

http://www.w3.org/2001/XMLSchema#string

Lukxmi Balathasan

http://www.w3.org/2001/XMLSchema#string

Naseer Qayum

http://www.w3.org/2001/XMLSchema#string

Ruth J Muschel

http://www.w3.org/2001/XMLSchema#string

Sonal Patel

http://www.w3.org/2001/XMLSchema#string

W Gillies McKenna

http://www.w3.org/2001/XMLSchema#string

P2860

Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer.

Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion

Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.

The development of combretastatin A4 phosphate as a vascular targeting agent.

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.

P304

6347-6354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-0657

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19622766

http://www.w3.org/2001/XMLSchema#string

P932

2825046

http://www.w3.org/2001/XMLSchema#string